Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the ...

Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to ...

CD Bioparticles launches comprehensive OMV-Based Bacterial Vaccines Development services for infectious disease and ...

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming ...

XI'AN CITY, SHAANXI PROVINCE, CHINA, February 5, 2026 /EINPresswire.com/ -- The nutritional supplement industry is ...

In an interview with Technology Networks, Dr. Daniel Reker discusses how machine learning is improving data-scarce areas of ...

National Pharmaceuticals Pricing Authority has directed pharma companies to cut MRPs of 17 drugs after the Budget 2026-27 exempted them from customs duty, ensuring the tax benefit is passed on to ...

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

Former FDA chief Scott Gottlieb warns Hims & Hers could face DOJ action for an unapproved oral GLP-1 semaglutide copy.

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...